Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous isatuximab plus VRd in newly diagnosed transplant-ineligible multiple myeloma
2024-517099-39-00Phase 2Authorised
- Sponsor
- CHU de Poitiers
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab, bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by CHU de Poitiers. Primary endpoint: Very good partial response rate. Planned start Nov 2024; status: authorised.
02
Drugs
isatuximabbortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-517099-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517099-39-00.